Author

R. Kalla

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

D. Babusis· 3 shared T. Cihlar· 3 shared A.-Q. Nguyen· 2 shared D. R. Martinez· 2 shared J. P. Bilello· 2 shared J. Y. Feng· 2 shared K. Chun· 2 shared K. L. Gully· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. Babusis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

D. R. Martinez, F. Moreira, M. R. Zweigart, K. L. Gully, G. De la Cruz, A. Brown, L. E. Adams, N. Catanzaro, B. Yount, T. J. Baric, M. Mallory, H. Conrad, S. R. May, S. Dong, T. D. Scobey, , T. P. Sheahan

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

bioRxiv · Jun 27, 2023 · PreprintMicrobiology

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys

R. L. Mackman, R. Kalla, D. Babusis, J. Pitts, K. T. Barrett, K. Chun, V. Du Pont, L. Rodriguez, J. Moshiri, Y. Xu, M. Lee, G. Lee, B. Bleier, A.-Q. Nguyen, B. M. O'Keefe, , T. Cihlar

bioRxiv · Apr 28, 2023Pharmacology & Toxicology

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

A. Schafer, D. R. Martinez, J. J. Won, F. R. Moreira, A. J. Brown, K. L. Gully, R. Kalla, K. Chun, V. Du Pont, D. Babusis, J. Tang, E. Murakami, R. Subramanian, K. T. Barrett, B. J. Bleier, , T. P. Sheahan

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.

R. Kalla, A. T. Adams, D. Bergemalm, S. Vatn, N. A. Kennedy, P. Ricanek, J. C. Lindstrom, A. Ocklind, F. Hjelm, N. T. Ventham, G.-T. Ho, C. Petren, IBD Character Consortium, D. Repsilber, J. D. Soderholm, , J. Satsangi

This study identifies a serum protein panel that distinguishes inflammatory bowel disease from non-IBD controls and predicts treatment escalation.

bioRxiv · Aug 31, 2020Immunology